[go: up one dir, main page]

BR9809304A - "formulações de proteìna c ativada" - Google Patents

"formulações de proteìna c ativada"

Info

Publication number
BR9809304A
BR9809304A BR9809304-5A BR9809304A BR9809304A BR 9809304 A BR9809304 A BR 9809304A BR 9809304 A BR9809304 A BR 9809304A BR 9809304 A BR9809304 A BR 9809304A
Authority
BR
Brazil
Prior art keywords
activated protein
formulations
protein formulations
activated
protein
Prior art date
Application number
BR9809304-5A
Other languages
English (en)
Other versions
BR9809304B1 (pt
Inventor
Andrew David Carlson
Theodore Arsay Sheliga
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR9809304A publication Critical patent/BR9809304A/pt
Publication of BR9809304B1 publication Critical patent/BR9809304B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Patente de Invenção: <B>"FORMULAçõES DE PROTEìNA C ATIVADA"<D>. A presente invenção refere-se à formulações farmacêuticas de proteína C ativada que contém também sacarose, cloreto de sódio e tampão de citrato de sódio num pH entre cerca de 5,5 e cerca de 6,5. As formulações de proteína C ativada da presente invenção são mais estáveis do que outras formulações de proteína C ativada e demonstraram apresentar menos produtos de degradação com o passar do tempo.
BRPI9809304-5A 1997-04-28 1998-04-24 formulação liofilizada estável, processo para preparação da mesma, bem como forma de dosagem unitária. BR9809304B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4525597P 1997-04-28 1997-04-28
US60/045,255 1997-04-28
PCT/US1998/008386 WO1998048818A1 (en) 1997-04-28 1998-04-24 Activated protein c formulations

Publications (2)

Publication Number Publication Date
BR9809304A true BR9809304A (pt) 2000-10-17
BR9809304B1 BR9809304B1 (pt) 2011-02-08

Family

ID=21936854

Family Applications (2)

Application Number Title Priority Date Filing Date
BR9809292-8A BR9809292A (pt) 1997-04-28 1998-04-24 Métodos aperfeiçoados para o processamento de proteìna c ativada
BRPI9809304-5A BR9809304B1 (pt) 1997-04-28 1998-04-24 formulação liofilizada estável, processo para preparação da mesma, bem como forma de dosagem unitária.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR9809292-8A BR9809292A (pt) 1997-04-28 1998-04-24 Métodos aperfeiçoados para o processamento de proteìna c ativada

Country Status (34)

Country Link
US (4) US6159468A (pt)
EP (2) EP0875252B1 (pt)
JP (2) JP4383546B2 (pt)
KR (2) KR100450856B1 (pt)
CN (2) CN1235638C (pt)
AR (2) AR012010A1 (pt)
AT (1) ATE285788T1 (pt)
AU (2) AU740753C (pt)
BR (2) BR9809292A (pt)
CA (2) CA2287267C (pt)
CO (2) CO4940438A1 (pt)
CZ (1) CZ298429B6 (pt)
DE (1) DE69828330T2 (pt)
DK (1) DK0875252T3 (pt)
EA (2) EA004881B1 (pt)
EG (1) EG23685A (pt)
ES (1) ES2234072T3 (pt)
HU (2) HUP0003401A3 (pt)
ID (2) ID23172A (pt)
IL (2) IL132325A (pt)
IN (2) IN183798B (pt)
MY (2) MY120984A (pt)
NO (2) NO995134L (pt)
NZ (2) NZ500346A (pt)
PE (2) PE86299A1 (pt)
PL (2) PL195090B1 (pt)
PT (1) PT875252E (pt)
SI (1) SI0875252T1 (pt)
SV (2) SV1998000051A (pt)
TR (2) TR199902529T2 (pt)
TW (2) TWI242443B (pt)
UA (2) UA55448C2 (pt)
WO (2) WO1998048822A1 (pt)
ZA (2) ZA983497B (pt)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630137B1 (en) * 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
CO4940438A1 (es) 1997-04-28 2000-07-24 Lilly Co Eli Metodos mejorados para el procesamiento de proteina c acti- vada
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6815533B1 (en) 1998-07-31 2004-11-09 Eli Lilly And Company Cryogranulation of activated protein C
CA2351067A1 (en) * 1998-11-13 2000-05-25 Eli Lilly And Company Method of treating heparin-induced thrombocytopenia
CA2351470A1 (en) * 1998-11-20 2000-06-02 Charles Jack Fisher Method of treating viral hemorrhagic fever
WO2000030676A1 (en) * 1998-11-23 2000-06-02 Eli Lilly And Company Method of treating sickle cell disease and thalassemia
ATE264113T1 (de) * 1998-12-10 2004-04-15 Lilly Co Eli Verwendung von protein c zur behandlung von thrombozytopenischer purpura und hämolytisches urämisches syndrom
US6758938B1 (en) * 1999-08-31 2004-07-06 Micron Technology, Inc. Delivery of dissolved ozone
US7204981B2 (en) * 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
EP1289543A2 (en) * 2000-05-24 2003-03-12 Eli Lilly And Company Formulations and methods for treating hypercoagulable states
JP4279554B2 (ja) 2001-02-19 2009-06-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｔ細胞エピトープの識別方法および低減された免疫原性を有する分子の製造方法
US7101982B2 (en) * 2001-03-30 2006-09-05 Immunex Corporation Control of ph transitions during chromatography
AU2002354951A1 (en) * 2001-07-19 2003-03-03 Dmi Biosciences, Inc. Use of copper chelators to inhibit the inactivation of protein c
US6838432B2 (en) 2001-09-19 2005-01-04 Oklahoma Medical Research Foundation Treatment of sepsis with TAFI
US20030073636A1 (en) * 2001-09-19 2003-04-17 Oklahoma Medical Research Foundation Method of treating diabetes
DE10149030A1 (de) * 2001-10-05 2003-04-10 Viscum Ag Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin
PL372138A1 (en) 2001-10-15 2005-07-11 Chiron Corporation Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (tfpi)
CN1607958A (zh) 2001-12-21 2005-04-20 诺和诺德医疗保健公司 因子ⅶ多肽的液体组合物
US20050143283A1 (en) * 2002-03-08 2005-06-30 Eli Lilly And Company Activated protein c formulations
EP1517698B2 (en) 2002-06-21 2017-12-06 Novo Nordisk Health Care AG STABILISED SOLID COMPOSITIONS OF FACTOR VIIa POLYPEPTIDES
CA2502378A1 (en) * 2002-10-29 2004-05-13 Alza Corporation Stabilized, solid-state polypeptide particles
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
JP4658041B2 (ja) * 2003-06-25 2011-03-23 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子ポリペプチドの液体組成物
SG150552A1 (en) * 2004-03-17 2009-03-30 Chiron Corp Treatment of severe community-acquired pneumonia by administration of tissue factor pathway inhibitor (tfpi)
EP1773371A4 (en) * 2004-07-23 2009-12-30 Univ Rochester ACTIVATED PROTEIN C INHIBITS SIDE EFFECTS OF PLASMINOGEN ACTIVATOR IN THE BRAIN
CA2612859A1 (en) * 2005-06-23 2006-12-28 The University Of British Columbia Coagulation factor iii polymorphisms associated with prediction of subject outcome and response to therapy
WO2007139553A1 (en) * 2006-05-31 2007-12-06 Genzyme Corporation Use of polysaccharides for promotion of enzymatic activity
EP2041338A4 (en) * 2006-06-09 2009-09-30 Univ British Columbia INTERFERON GAMMA POLYMORPHISMS AS INDICATORS OF RESULT IN SERIOUSLY SICK SUBJECTS
BRPI0808259A2 (pt) * 2007-03-05 2014-07-08 Cadila Healthcare Ltd "formulação, processo de liofilização, formulação liofilizada, e processo para preparar uma formulação liofilizada"
NZ580379A (en) 2007-03-29 2012-10-26 Abbott Lab Crystalline anti-human il-12 antibodies
CA2707483A1 (en) * 2007-11-30 2009-06-11 Wolfgang Fraunhofer Protein formulations and methods of making same
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
CA2712057A1 (en) * 2008-01-15 2009-07-23 The University Of British Columbia Protein c rs2069915 as a response predictor to survival and administration of activated protein c or protein c-like compound
KR20110096553A (ko) * 2008-11-28 2011-08-30 아보트 러보러터리즈 안정한 항체 조성물 및 이의 안정화 방법
WO2012068519A2 (en) 2010-11-19 2012-05-24 Sirius Genomics Inc. Markers associated with response to activated protein c administration, and uses thereof
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
EP2834635A4 (en) 2012-04-03 2015-09-02 Smiths Medical Asd Inc COMPOSITIONS WITH A HEPARINE ACCUMULATIVE AND METHOD THEREFOR
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
CA2877745C (en) 2012-07-04 2021-11-30 The University Of Sydney Treatment of inflammatory skin disorders
US9206390B2 (en) 2012-09-02 2015-12-08 Abbvie, Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
JP2017513944A (ja) 2014-04-16 2017-06-01 ジージー バイオテック エルエルシー 異常な皮膚瘢痕化の治療
JP6873387B2 (ja) 2014-04-16 2021-05-19 ジージー バイオテック エルエルシー 創傷治癒に対するａｐｃ類似体の使用
US11058750B2 (en) 2015-12-03 2021-07-13 Mor Research Applications Ltd. Compositions and methods for treatment of ocular diseases
JP7109427B2 (ja) * 2016-06-01 2022-07-29 セルヴィエ アイピー ユーケー リミテッド ポリアルキレンオキシド－アスパラギナーゼの製剤ならびにその製造法および使用法
CN108159399B (zh) * 2017-12-29 2020-07-24 华中科技大学同济医学院附属同济医院 一种凝血蛋白酶aPC在防治糖尿病心肌病药物中的应用
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US4849403A (en) * 1985-05-29 1989-07-18 Pentapharm Ag Protein C activator, methods of preparation and use thereof
US5516650A (en) 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
AT399095B (de) * 1986-03-27 1995-03-27 Vukovich Thomas Dr Verfahren zur auftrennung von proteinen mittels gradientenelution und vorrichtung zur durchführung des verfahrens
US5175087A (en) * 1987-07-06 1992-12-29 Biopool International, Inc. Method of performing tissue plasminogen activator assay
CA1329760C (en) * 1987-10-29 1994-05-24 Ted C. K. Lee Plasma and recombinant protein formulations in high ionic strength media
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
JP2739050B2 (ja) * 1988-01-28 1998-04-08 ヘキスト薬品工業株式会社 抗血液凝固剤
JPH01226900A (ja) * 1988-03-08 1989-09-11 Green Cross Corp:The プロテインｃの精製方法
DE3823519A1 (de) * 1988-07-12 1990-01-18 Basf Ag Verfahren zur reinigung von aktiviertem protein c
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
US5093117A (en) * 1989-01-24 1992-03-03 Baxter International Inc. Compositions and method for the treatment or prophylaxis of sepsis or septic shock
WO1991012320A1 (en) * 1990-02-09 1991-08-22 Zymogenetics, Inc. Activated protein c with truncated light chain
IL97312A (en) * 1990-02-23 1999-01-26 Lilly Co Eli A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
US5040862A (en) 1990-05-07 1991-08-20 Corning Incorporated Method of trimming optical power
AT402262B (de) * 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
US5413732A (en) * 1991-08-19 1995-05-09 Abaxis, Inc. Reagent compositions for analytical testing
MY110664A (en) 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
DE4234295A1 (de) * 1992-10-12 1994-04-14 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5395923A (en) * 1993-02-23 1995-03-07 Haemacure-Biotech, Inc. Process for the obtention of a biological adhesive made of concentrated coagulation factors by "salting-out"
JP2886061B2 (ja) * 1993-10-29 1999-04-26 財団法人化学及血清療法研究所 プロテインｃもしくは活性化プロテインｃの安定化方法及び安定化組成物
JP3043558B2 (ja) * 1993-10-29 2000-05-22 財団法人化学及血清療法研究所 ヒト活性化プロテインｃ調製物及びその製法
JPH07165605A (ja) * 1993-12-16 1995-06-27 Teijin Ltd 活性化プロテインｃバイアル
NZ270271A (en) * 1994-01-05 1996-07-26 Lilly Co Eli Minimizing protein c degradation
JPH08301786A (ja) * 1995-05-11 1996-11-19 Mochida Pharmaceut Co Ltd 吸収性骨疾患予防・治療剤
WO1997020043A1 (en) 1995-11-30 1997-06-05 Zymogenetics, Inc. Protein c production in transgenic animals
CO4940438A1 (es) 1997-04-28 2000-07-24 Lilly Co Eli Metodos mejorados para el procesamiento de proteina c acti- vada
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders

Also Published As

Publication number Publication date
KR20010020242A (ko) 2001-03-15
PT875252E (pt) 2005-03-31
MY120984A (en) 2005-12-30
HUP0003401A3 (en) 2003-01-28
BR9809304B1 (pt) 2011-02-08
UA55448C2 (uk) 2003-04-15
AU7161898A (en) 1998-11-24
HU224826B1 (en) 2006-02-28
SV1998000050A (es) 1999-01-13
NO995134L (no) 1999-12-21
HUP0100284A3 (en) 2003-08-28
CO4950523A1 (es) 2000-09-01
TW585871B (en) 2004-05-01
EA004881B1 (ru) 2004-08-26
DE69828330D1 (de) 2005-02-03
PE86299A1 (es) 1999-09-17
KR20010020325A (ko) 2001-03-15
HK1016472A1 (en) 1999-11-05
DE69828330T2 (de) 2005-10-13
US6436397B1 (en) 2002-08-20
CO4940438A1 (es) 2000-07-24
IL132502A0 (en) 2001-03-19
EP0875252A2 (en) 1998-11-04
PL195090B1 (pl) 2007-08-31
CA2288143A1 (en) 1998-11-05
CN1261280A (zh) 2000-07-26
SI0875252T1 (en) 2005-06-30
PL336420A1 (en) 2000-06-19
AU7258998A (en) 1998-11-24
NO995198L (no) 1999-10-25
IL132325A (en) 2005-07-25
NO995198D0 (no) 1999-10-25
DK0875252T3 (da) 2005-04-25
ID22933A (id) 1999-12-16
AU740753C (en) 2002-10-10
JP2001527543A (ja) 2001-12-25
EA199900979A1 (ru) 2000-06-26
CZ381099A3 (cs) 2000-03-15
PL336889A1 (en) 2000-07-17
KR100564189B1 (ko) 2006-03-27
CN1227025C (zh) 2005-11-16
WO1998048822A1 (en) 1998-11-05
CA2287267A1 (en) 1998-11-05
ES2234072T3 (es) 2005-06-16
BR9809292A (pt) 2000-07-04
CA2288143C (en) 2012-08-21
ID23172A (id) 2000-03-23
WO1998048818A1 (en) 1998-11-05
ZA983497B (en) 1999-10-25
NO995134D0 (no) 1999-10-21
TWI242443B (en) 2005-11-01
AR012010A1 (es) 2000-09-13
PE84799A1 (es) 1999-09-16
EP0875252B1 (en) 2004-12-29
MY118591A (en) 2004-12-31
US6159468A (en) 2000-12-12
JP4383547B2 (ja) 2009-12-16
TR199902631T2 (xx) 2000-01-21
IN187157B (pt) 2002-02-16
CZ298429B6 (cs) 2007-10-03
AU740753B2 (en) 2001-11-15
EP0875563A3 (en) 2000-08-02
AU743531B2 (en) 2002-01-31
CN1254284A (zh) 2000-05-24
ZA983496B (en) 1999-10-25
EP0875252A3 (en) 2000-07-26
ATE285788T1 (de) 2005-01-15
CN1235638C (zh) 2006-01-11
UA73071C2 (en) 2005-06-15
NZ337828A (en) 2001-06-29
EA199900980A1 (ru) 2000-04-24
NZ500346A (en) 2001-08-31
IL132325A0 (en) 2001-03-19
EP0875563A2 (en) 1998-11-04
HUP0100284A2 (hu) 2001-06-28
HUP0003401A2 (hu) 2001-02-28
SV1998000051A (es) 1998-12-11
US6395270B1 (en) 2002-05-28
US6162629A (en) 2000-12-19
TR199902529T2 (xx) 2000-02-21
JP2001524111A (ja) 2001-11-27
CA2287267C (en) 2006-08-15
AR015598A1 (es) 2001-05-16
KR100450856B1 (ko) 2004-10-02
EA002149B1 (ru) 2001-12-24
JP4383546B2 (ja) 2009-12-16
PL195642B1 (pl) 2007-10-31
IN183798B (pt) 2000-04-15
EG23685A (en) 2007-05-09

Similar Documents

Publication Publication Date Title
BR9809304A (pt) &#34;formulações de proteìna c ativada&#34;
BR9808787A (pt) Moduladores receptores de aminoácidos excitadores
NO2016024I2 (no) Farmasøytisk blanding eller assosisjon som inneholder som aktive ingredienser: (1) ceftazidim eller et salt derav, og (2) avibaktam eller et farmasøytisk akseptabelt salt derav
FI973039A7 (fi) Uusia farnesyylitransferaasin inhibiittoreita, niiden valmistus ja niitä sisältäviä farmaseuttisia koostumuksia
EP0753296A3 (en) Oral formulations containing S (+) - ibuprofen
BR9917007A (pt) Moduladores de ccr5
ES2195344T3 (es) Composicion farmaceutica que presenta una actividad antitumoral mejorada y/o efectos secundarios reducidos, que contiene un agente antitumoral y un derivado de acido hidroximico.
NO993519L (no) Fenofibrat farmasöytisk blanding som har höy biotilgjengelighet og fremgangsmÕte for fremstilling av den
CY1112274T1 (el) Νεοι ολιγοσακχαριτες, η παρασκευh τους και οι φαρμακευτικες συνθεσεις οι οποιες τους περιεχουν
ITRM960810A0 (it) Composizioni farmaceutiche contenenti ciclosporine o macrolidi
BR9914044A (pt) ésteres tetrahidropirido
JPH1072351A5 (pt)
ATE195721T1 (de) Lipopolyamine als transfectionsmittel und ihre pharmazeutischen anwendungen
BR0109943A (pt) Composições farmacêuticas
NO974321D0 (no) Nodulisporsyrederivater
BR9606674B1 (pt) novo derivado de composto de antraciclina e preparação farmacêutica contendo o mesmo.
BR9814523A (pt) &#34;composição farmacêutica contendo cloridrato de bupropion e um estabilizador de ácido inorgânico&#34;
AU5537096A (en) Isolated frpb nucleic acid molecule and vaccine
ZA9811833B (en) Pharmaceutical compositions of uridine triphosphate.
BG103968A (en) Pharmaceutical antiviral composition containing glycirricinic acid and at least one protein with antiviral activity
NO20005332L (no) 1,6-GPS-(6-O-α-D-glukopyranosyl-D-sorbit) og 1,1-GPM-(1-O-α-D-glukopyranosyl-D-mannit)-holdig sukkeralkoholblanding for bruk som terapeutisk aktivt stoff samt legemiddel inneholdende nevnte blanding
WO2002062304A3 (de) Kosmetische und/oder pharmazeutische mittel acylierte aminosäure und proteinkondensat enthaltend.
NO980296D0 (no) Forbedrede terapeutiske midler
BR9910454A (pt) Preparações efervescentes
DK0977871T3 (da) Neurotrypsin

Legal Events

Date Code Title Description
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA A CLASSIFICACAO DE A61K 31/725.

Ipc: A61K 38/46 (2007.01), A61K 38/48 (2007.01), A61K 4

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 08/02/2011, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 17A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2308 DE 31-03-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.